LGVN

MKT CAP:$22M

Longeveron Inc.

Market Cap

$22M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$0.98+$0.38 (+64.65%)

Apr 23, 2026

Company Details

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derive...

CEO

Stephen H. Willard

IPO Date

Feb 12, 2021

Website

www.longeveron.com

Key Metrics TTM

Revenue

$1M

-49.9% YoY

Net Income

-$23M

EPS (Diluted)

-$1.30

Free Cash Flow

-$19M

Revenue / Share

$0.05

Gross Margin

43.7%

Operating Margin

-1942.2%

Net Margin

-1893.6%

FCF Margin

-1591.2%

P/S

18.5x

P/E

—

Earnings Reports

Q1 2026

May 8, 2026

PENDING

FY 2025

Mar 17, 2026

$1M-49.9%EPS -$1.29

Q4 2025

Mar 17, 2026

$365.0K-39.5%EPS -$0.24

Q3 2025

Nov 4, 2025

$137.0K-82.3%EPS -$0.39

Q2 2025

Aug 13, 2025

$316.0K-32.5%EPS -$0.33

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$370.0K	$165.0K	-$3M
Q2 22	$466.0K	$160.0K	-$4M
Q3 22	$265.0K	$92.0K	-$5M
Q4 22	$121.0K	-$55.0K	-$5M
Q1 23	$238.0K	$35.0K	-$5M
Q2 23	$217.0K	$93.0K	-$6M
Q3 23	$150.0K	$54.0K	-$5M
Q4 23	$63.0K	-$2.0K	-$5M
Q1 24	$548.0K	$329.0K	-$4M
Q2 24	$468.0K	$344.0K	-$4M
Q3 24	$773.0K	$682.0K	-$5M
Q4 24	$603.0K	$530.0K	-$4M
Q1 25	$381.0K	$275.0K	-$5M
Q2 25	$316.0K	$146.0K	-$5M
Q3 25	$137.0K	$125.0K	-$7M
Q4 25	$365.0K	-$22.0K	-$5M

Valuation

Quarter	P/S	P/E
Q1 22	107.3x	—
Q2 22	104.5x	—
Q3 22	60.2x	—
Q4 22	56.8x	—
Q1 23	50.5x	—
Q2 23	81.8x	—
Q3 23	74.5x	—
Q4 23	48.5x	—
Q1 24	19.0x	—
Q2 24	17.4x	—
Q3 24	15.6x	—
Q4 24	11.0x	—
Q1 25	10.4x	—
Q2 25	9.4x	—
Q3 25	8.0x	—
Q4 25	7.9x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$4M	-$4M
Q2 22	-$3M	-$3M
Q3 22	-$4M	-$5M
Q4 22	-$2M	-$2M
Q1 23	-$6M	-$6M
Q2 23	-$5M	-$5M
Q3 23	-$5M	-$5M
Q4 23	-$4M	-$4M
Q1 24	-$3M	-$3M
Q2 24	-$5M	-$5M
Q3 24	-$3M	-$3M
Q4 24	-$3M	-$3M
Q1 25	-$5M	-$5M
Q2 25	-$4M	-$4M
Q3 25	-$5M	-$5M
Q4 25	-$5M	-$5M

Capital Expenditures

Quarter	CapEx
Q1 22	$47.0K
Q2 22	$78.0K
Q3 22	$378.0K
Q4 22	$66.0K
Q1 23	$42.0K
Q2 23	$92.0K
Q3 23	$115.0K
Q4 23	$259.0K
Q1 24	$47.0K
Q2 24	$196.0K
Q3 24	$430.0K
Q4 24	$13.0K
Q1 25	$27.0K
Q2 25	$161.0K
Q3 25	$57.0K
Q4 25	$188.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	-1.6%	-1.8%
Q2 22	-4.7%	-15.6%
Q3 22	+14.2%	+6.1%
Q4 22	-42.1%	+26.4%
Q1 23	-35.7%	+31.6%
Q2 23	-53.4%	+26.5%
Q3 23	-43.4%	-2.6%
Q4 23	-47.9%	+2.6%
Q1 24	+130.3%	-6.4%
Q2 24	+115.7%	-33.1%
Q3 24	+415.3%	+2.1%
Q4 24	+857.1%	-11.2%
Q1 25	-30.5%	+19.9%
Q2 25	-32.5%	+44.0%
Q3 25	-82.3%	+37.3%
Q4 25	-39.5%	+18.0%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$491.0K	132.7%
Q2 22	$900.0K	193.1%
Q3 22	$500.0K	188.7%
Q4 22	$306.0K	252.9%
Q1 23	$421.0K	176.9%
Q2 23	$700.0K	322.6%
Q3 23	$499.0K	332.7%
Q4 23	$413.0K	655.6%
Q1 24	$295.0K	53.8%
Q2 24	$200.0K	42.7%
Q3 24	$1M	181.1%
Q4 24	$2M	386.1%
Q1 25	$340.0K	89.2%
Q2 25	$513.0K	162.3%
Q3 25	$0	0.0%
Q4 25	$376.0K	103.0%

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 22	$1M	$2M	$287.0K	—
Q2 22	$2M	$2M	$234.0K	—
Q3 22	$3M	$2M	$245.0K	—
Q4 22	$3M	$2M	$285.0K	—
Q1 23	$3M	$2M	—	—
Q2 23	$2M	$4M	—	—
Q3 23	$2M	$3M	$280.0K	—
Q4 23	$2M	$3M	$203.0K	—
Q1 24	$2M	$2M	—	—
Q2 24	$2M	$2M	—	—
Q3 24	$2M	$3M	—	—
Q4 24	$2M	$3M	—	—
Q1 25	$3M	$3M	—	—
Q2 25	$3M	$3M	—	—
Q3 25	$4M	$4M	—	—
Q4 25	$2M	—	—	$3M

Revenue Segments

Quarter

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$22M	$8M	$31M
Q2 22	$20M	$7M	$27M
Q3 22	$14M	$9M	$22M
Q4 22	$11M	$9M	$20M
Q1 23	$5M	$9M	$14M
Q2 23	$3M	$6M	$9M
Q3 23	$2M	$2M	$4M
Q4 23	$5M	$412.0K	$5M
Q1 24	$2M	$351.0K	$2M
Q2 24	$12M	$0	$12M
Q3 24	$23M	$0	$23M
Q4 24	$19M	$0	$19M
Q1 25	$14M	$0	$14M
Q2 25	$10M	$0	$10M
Q3 25	$9M	$0	$9M
Q4 25	$5M	$0	$5M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	2M	+4.5%	+19.6%
Q2 22	2M	+0.2%	+10.2%
Q3 22	2M	+0.3%	+9.9%
Q4 22	2M	+0.1%	+5.0%
Q1 23	2M	+0.1%	+0.6%
Q2 23	2M	+0.3%	+0.8%
Q3 23	2M	+0.3%	+0.8%
Q4 23	0	-100.0%	-100.0%
Q1 24	3M	—	+19.5%
Q2 24	7M	+159.0%	+208.4%
Q3 24	14M	+109.3%	+543.5%
Q4 24	15M	+9.3%	—
Q1 25	15M	+0.4%	+494.8%
Q2 25	15M	+0.4%	+130.6%
Q3 25	18M	+22.4%	+34.8%
Q4 25	23M	+24.8%	+54.0%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$20.6K	18
Q2 22	$25.9K	18
Q3 22	$14.7K	18
Q4 22	$6.4K	19
Q1 23	$12.5K	19
Q2 23	$11.4K	19
Q3 23	$7.9K	19
Q4 23	$2.7K	23
Q1 24	$23.8K	23
Q2 24	$20.3K	23
Q3 24	$33.6K	23
Q4 24	$24.1K	25
Q1 25	$15.2K	25
Q2 25	$12.6K	25
Q3 25	$5.5K	25
Q4 25	$2	200K

Revenue / Employee